There is no better tap than Brainstorm Cell Therapeutics, Inc. (BCLI) Stock
Maxim Group raised the price target for the Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) stock from “a Hold” to “a Buy”. The rating was released on February 04, 2021, according to finviz. The research report from Maxim Group has reiterated the stock to Buy, with a price target set at $6. The stock was reiterated by […]
Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) Stock upgraded by Maxim Group
Maxim Group raised the price target for the Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) stock from “a Hold” to “a Buy”. The rating was released on February 04, 2021, according to finviz. The research report from Maxim Group has reiterated the stock to Buy, with a price target set at $6. The stock was reiterated by […]
Does Brainstorm Cell Therapeutics, Inc. (BCLI) Stock have plenty of room for growth?
Maxim Group raised the price target for the Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) stock from “a Hold” to “a Buy”. The rating was released on February 04, 2021, according to finviz. The research report from Maxim Group has reiterated the stock to Buy, with a price target set at $6. The stock was reiterated by […]
Recent trade makes Brainstorm Cell Therapeutics, Inc. (BCLI) Stock an appealing buy
Maxim Group raised the price target for the Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) stock from “a Hold” to “a Buy”. The rating was released on February 04, 2021, according to finviz. The research report from Maxim Group has reiterated the stock to Buy, with a price target set at $6. The stock was reiterated by […]
Brainstorm Cell Therapeutics, Inc. (BCLI) Stock creates opportunities due to its volume and complexity
Maxim Group raised the price target for the Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) stock from “a Hold” to “a Buy”. The rating was released on February 04, 2021, according to finviz. The research report from Maxim Group has reiterated the stock to Buy, with a price target set at $6. The stock was reiterated by […]
Brainstorm Cell Therapeutics, Inc. (BCLI) Stock Has More Upside Than Fundamentals Suggest
Maxim Group raised the price target for the Brainstorm Cell Therapeutics, Inc. (NASDAQ:BCLI) stock from “a Hold” to “a Buy”. The rating was released on February 04, 2021, according to finviz. The research report from Maxim Group has reiterated the stock to Buy, with a price target set at $6. The stock was reiterated by […]
